TALOPH(SH:600222)2014-10-24 16:00Financial Performance - Operating revenue decreased by 3.31% to CNY 871,857,012.45 for the year-to-date period[7] - Net profit attributable to shareholders decreased by 44.16% to CNY 11,217,574.74 year-on-year[7] - Basic earnings per share fell by 44.20% to CNY 0.0226[9] - The weighted average return on net assets decreased by 1.72 percentage points to 1.07%[7] - The company reported a significant decrease in net profit due to increased operational costs and market challenges[7] - The net profit attributable to the parent company decreased by 44.16% to RMB 11,217,574.74, mainly due to the impact of downstream pharmaceutical distributors undergoing new GSP certification[16] - The company reported a net loss of CNY 4,243,104.11, compared to a net profit of CNY 2,356,927.36 in the same period last year[48] - The company reported an operating profit of CNY 4,892,787.13 for the first nine months of 2014, down from CNY 9,658,108.70 in the same period last year[48] Cash Flow - Net cash flow from operating activities turned negative at CNY -42,071,162.27, a decrease of 152.28% compared to the same period last year[7] - The company experienced a cash outflow from operating activities of CNY 42,071,162.27 in Q3 2014, contrasting with a cash inflow of CNY 80,470,865.58 in the same quarter of the previous year[52] - Cash generated from operating activities was $9,556,083.74, down from $74,374,502.48, reflecting a decline of about 87.1%[56] - The net cash flow from financing activities was $62,046,476.28, compared to $323,462,338.75, indicating a decline of about 80.8%[57] - The ending balance of cash and cash equivalents was $395,145,121.80, down from $500,479,611.25, a decrease of approximately 21.1%[57] Assets and Liabilities - Total assets increased by 8.80% to CNY 2,125,469,349.59 compared to the end of the previous year[7] - The company's total liabilities amounted to CNY 974,816,143.76, up from CNY 861,221,793.10, which is an increase of approximately 13.2%[36] - The company's current assets totaled CNY 1,304,621,068.91 at the end of the reporting period, up from CNY 1,184,856,352.15 at the start of the year, indicating a growth of about 10.1%[34] - The company's cash and cash equivalents decreased to CNY 437,214,745.37 from CNY 455,622,876.54, representing a decline of approximately 4.0%[34] - The company's total liabilities rose to CNY 752,412,747.05 in Q3 2014, compared to CNY 658,077,150.01 in Q3 2013, an increase of 14.3%[40] Shareholder Information - The total number of shareholders reached 42,142 by the end of the reporting period[11] - The largest shareholder, Zhengzhou Zhongsheng Industrial Group Co., Ltd., holds 26.55% of the shares[11] - The company disclosed that the controlling shareholder subscribed for 36.9 million shares, representing 7.43% of the total shares post-issuance[24] Government Support and Commitments - The company received government subsidies amounting to CNY 1,314,500.00 during the reporting period[10] - The controlling shareholder, Zhengzhou Zhongsheng Industrial Group, committed not to engage in any competitive business activities with the company in China[20] - The company has committed to distributing at least 10% of its distributable profits in cash annually, provided that it meets certain conditions regarding profitability and cash flow[24] Operational Changes and Future Plans - The company plans to expand its market presence and focus on cultivating unique products such as dual-golden compound and dual-yellow oral liquid for children[17] - The company has undertaken to comply with the regulations set forth by the China Securities Regulatory Commission and the stock exchange regarding related party transactions[23] - The company has stated that it will not reduce its holdings during the share repurchase period and legal timeframe[24]